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Abstract
Introduction: The programmed cell death 1 (PD-1) protein is a critical regulator of T-cell activation and is also an
important therapeutic target for autoimmune diseases. Little is known about the regulation and functional properties
of the soluble PD-1 (sPD-1) variant. The aim of this study was to examine the role of sPD-1 in the regulation of human
and murine rheumatoid arthritis (RA).
Methods: Expression of cytokines and sPD-1 in sera, synovial fluid, and peripheral blood (PB) mononuclear cells of
patients with RA were analyzed by enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
PD-1 function was assessed in PB T cells after stimulation of the cells with anti-CD3 and PD-L1-Fc to crosslink PD-1.
Recombinant PD-1-Fc was injected intraperitoneally into DBA/1 mice with collagen-induced arthritis (CIA) to analyze
the function of sPD-1 in vivo.
Results: High concentrations of sPD-1 were found in sera and synovial fluid of patients with RA. The levels of serum
sPD-1 were significantly correlated with titers of rheumatoid factor (RF) (r = 0.306, p = 0.005) and 28-joint Disease
Activity Score (r = 0.545, p < 0.001). Further characterization of sPD-1 revealed that it functionally blocked the inhibitory
effect of membrane-bound PD-1 on T-cell activation. Interferon γ, tumor necrosis factor α, and interleukin 17A were
identified as inducers of sPD-1 in vitro. Moreover, PD-1-Fc enhanced proinflammatory cytokine expression, generation
of Th1 cells and Th17 cells, and joint pathology in a CIA model.
Conclusions: sPD-1 regulates peripheral T-cell responses in both human and murine RA. Thus, sPD-1 may represent an
additional biomarker or target in immunomodulatory therapy for RA.
Introduction
Rheumatoid arthritis (RA) is one of the most common
autoimmune diseases, affecting 1 % of the population
worldwide [1, 2]. Pathogenic T cells, such as Th1 and
Th17 cells, are considered to be critical to the initiation
and maintenance of the disease [3–5]. These cells are
thought to be triggered locally in an antigen-specific
manner, resulting in breakdown of tolerance, synovial
inflammation, and autoantibody production [6–9].
Programmed cell death 1 (PD-1; also called CD279),
which is inducibly expressed on CD4+ T cells, CD8+ T
cells, natural killer T cells, B cells, and activated mono-
cytes, is a type I membrane protein that delivers inhibi-
tory signals to T cells upon binding of its ligands PD-L1
or PD-L2 [10–13]. PD-1 has been shown to be import-
ant for self-tolerance, because spontaneous autoimmune
diseases develop in PD-1−/− mice [14–16]. In addition,
genetic studies revealed that there is an association be-
tween polymorphisms in the PDCD1 gene (which en-
codes PD-1) and susceptibility to autoimmune diseases
[17–19], suggesting that PD-1 may play an important
role in the development of autoimmune diseases. PD-L1
is widely expressed in activated endothelial and epithelial
cells, and it is therefore thought to be important for the
fine-tuning of lymphocyte activation at the level of
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synovial tissue [20, 21]. Increased numbers of PD-1+ and
PD-L1+ cells were found in the synovium of patients
with active RA [22–24].
There are four alternatively spliced PDCD-1 messenger
RNA (mRNA) transcripts in addition to the full-length
isoform (flPD-1): PD-1 lacking exon 2 (PD-1Δex2), PD-1
lacking exon 3 (PD-1Δex3), PD-1 lacking exons 2 and 3
(PD-1Δex2,3), and PD-1 lacking exons 2, 3, and 4
(PD-1Δex2,3,4). Soluble PD-1 (sPD-1) is encoded by
PD-1Δex3, which retains the extracellular domain but
lacks the transmembrane domain [25]. Previous studies
have shown that sPD-1 promotes T-cell responses by
blocking the PD-1/PD ligand pathway [26–31]. Although
the function of sPD-1 in antitumor and antiviral immunity
has been studied extensively [26–30], its clinical relevance
and function in RA is unknown. It was reported that sPD-
1 occurred at high concentrations in sera and synovial
fluid (SF) of patients with RA, and PD-1 levels were found
to correlate with titers of rheumatoid factor in (RF)
patients with RA [32, 33].
We designed the present study to determine the role
of sPD-1 in RA and to test the hypothesis that overex-
pression of this molecule may contribute to T-cell
hyperactivity within the inflamed joint. We examined
the clinical significance of sPD-1 in patients with RA by
determining sPD-1 levels in serum samples. Recombin-
ant fusion proteins corresponding to the extracellular
domains (inclusive of the PD-1Δex3 variant) of PD-1
molecule were tested in T-cell proliferation assays using
RA-derived peripheral blood mononuclear cells (PBMCs).
The role of sPD-1 in RA was further studied by generating
collagen-induced arthritis (CIA) in DBA/1 mice and by
using PD-1-Fc to block PD-1 signaling in vivo. Our data
suggest that sPD-1 may be a promising biomarker for
diagnosing and determining the prognosis of RA. sPD-1
and inflammatory mediators of patients with RA signifi-
cantly attenuated or reversed T-cell suppression mediated
by PD-L1-Fc, verifying that sPD-1 acts as a natural blocker
of PD-1/PD-L1 signaling and that soluble factors may
interfere with this negative pathway.
Materials and methods
Patients and specimens
A total of 83 patients with RA were included in the
study (Table 1). All patients fulfilled the American
College of Rheumatology criteria for RA. This group in-
cluded 61 females and 22 males with mean disease dur-
ation of 12.1 ± 8.0 years. The mean age of the patients
was 58.30 ± 13.01 years. They were recruited from in-
patient and outpatient clinics at the rheumatology de-
partments of the First and Third Affiliated Hospitals of
Soochow University. Disease history was recorded for all
patients, including presenting symptoms, affected joint
counts, and medication history. The activity of disease
was evaluated by calculation of 28-joint Disease Activity
Score (DAS28) [34]. The level of RA disease activity can
be interpreted as low (Lo-RA; 2.6 ≤DAS28 ≤ 3.2), mod-
erate (Mo-RA; 3.2 < DAS28 ≤ 5.1), or high (Hi-RA;
Table 1 Clinical information about patients with RA and controls
Group RA OA HC
Sample size, n 83 67 88
Age, yr, mean ± standard deviation 58.30 ± 13.01 56.78 ± 13.98 55.73 ± 15.19
Sex, n
Male 22 17 20
Female 61 50 68
Mean duration of disease, mo (range) 53.27 (1–456) 46.31 (1–323) –
Stages of disease, n
Early RA (≤12 mo) 30
Late RA (>12 mo) 53
Activity of disease, n
Remission (DAS28 < 2.6) 10 – –
Low (2.6≤ DAS28≤ 3.2) 16 – –
Moderate (3.2 < DAS28≤ 5.1) 45 – –
High (DAS28 > 5.1) 12 – –
Manifestations of disease, n
Extraarticular 23 – –
Limited joint manifestations 60 – –
Drug use before study – – –
RA rheumatoid arthritis, OA osteoarthritis, HC healthy controls, DAS28 28-joint Disease Activity Score
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DAS28 > 5.1), and a DAS28 < 2.6 can be considered as
remission (Re-RA), according to the European League
against Rheumatism criteria. According to extraarticular
involvement, the subjects were divided into patients with
RA with limited joint manifestations and those with
extraarticular manifestations. Eight of the patients re-
ceived methotrexate (MTX) therapy (10 mg/week for
20 weeks by oral administration, including follow-up
periods of 16 and 32 weeks). None of the patients had
received steroid or immunosuppressive drugs within
1 year before the study period. Complete sets of paired
SF and peripheral blood were obtained from 15 of the
83 patients for paired analyses. Additional sets of SF and
paired serum specimens (no cells) derived from the
remaining 68 patients with RA were used only for ana-
lyses of protein concentrations of sPD-1 by enzyme-
linked immunosorbent assay (ELISA). Complete sets of
paired SF and peripheral blood samples from a total of
67 patients with osteoarthritis (OA) were also included
in the study. Control PBMCs and sera were obtained
from a group of 88 healthy individuals who were
matched for sex ratio and mean age with the patient
group from the same hospitals and who had not received
immunosuppressive or immunomodulatory drugs for
various reasons for at least 2 months before the time of
sample collection. Informed consent was obtained from
all subjects before sample collection. The study protocol
and consent form were approved by the Institutional
Medical Ethics Review Board of Soochow University. SF
was centrifuged at 350 × g for 3 minutes, and superna-
tants were collected and immediately stored at −80 °C
until use. Mononuclear cells were prepared by Ficoll-
Hypaque separation (GE Healthcare Life Sciences, Little
Chalfont, UK) in all cases from blood specimens of pa-
tients with RA and controls using the standard protocol.
Preparation of mononuclear cells and isolation of CD4+ T
lymphocytes
PBMCs were isolated from patients with RA or controls.
Cells were washed by centrifugation in RPMI 1640
medium and subsequently resuspended in cold
phosphate-buffered saline (PBS) containing 2.5 % fetal
bovine serum (FBS) at a cell density of 1 × 107/ml. CD4+
T cells were prepared from freshly isolated PBMCs by
depleting cells expressing CD8, CD14, CD16, CD19,
CD36, CD56, CD123, γ/δ-T-cell receptors, and glyco-
phorin A using No-Touch T-cell isolation kits (Miltenyi
Biotec, Bergisch Gladbach, Germany). The purity of
CD4+ T cells was 95–98 % as determined by flow cytom-
etry using specific antibodies.
T-cell stimulation
Purified T-cell preparations derived from peripheral
blood of patients with RA or controls were cultured at
1 × 106/ml in RPMI 1640 medium containing 10 % FBS
in the presence of 1 μg/ml anti-CD3 monoclonal anti-
body (mAb) (clone OKT-3; eBioscience, San Diego, CA,
USA) and 0.05 μg/ml anti-CD28 mAb (clone CD28.2;
eBioscience). Cells were maintained at 37 °C in a 5 %
CO2 atmosphere for 48 h and were then harvested for
RNA extraction before real-time polymerase chain reac-
tion (PCR) analysis.
Induction of the expression of PD-1 isoforms
PBMCs from healthy individuals were cultured in 24-
well plates at 1 × 106/ml in RPMI 1640 medium contain-
ing 10 % FBS in the presence or absence of a panel of
recombinant human cytokines [interferon (IFN)-γ, inter-
leukin (IL)-17A, or tumor necrosis factor (TNF)-α; R&D
Systems, Minneapolis, MN, USA), respectively, at the in-
dicated concentrations. Cells were kept in culture at 37 °C
in a 5 % CO2 atmosphere for 12 h or 24 h and were then
harvested for isolation of CD4+ T cells before real-time
PCR analysis.
RNA extraction and real-time PCR
Total RNA was isolated from cell pellets using an
RNeasy Mini Kit (Qiagen, Hilden, Germany). Genomic
DNA was removed using RNase-Free DNase (Qiagen).
RNA was stored at −80 °C. First-strand cDNA synthesis
was performed using a Sensiscript Reverse Transcription
Kit (Qiagen) with random hexamers as the primers.
mRNA expression of the genes encoding IFN-γ, TNF-α,
IL-2, IL-10, IL-17A, IL-21, flPD-1, and PD-1Δex3 mRNA
was determined by real-time PCR using SYBR Green
Master Mix (Applied Biosystems, Foster City, CA, USA).
Data were collected and quantitatively analyzed on an
ABI PRISM 7900 sequence detection system (Applied
Biosystems). The GAPDH gene was used as an endogen-
ous control to normalize for differences in the amount
of total RNA in each sample.
Detection of soluble PD-1 and cytokine molecules by
ELISA
Concentrations of sPD-1 were measured quantitatively
in SF and sera using ELISA according to our established
protocol. For sPD-1, Costar ELISA 96-well plates (Fisher
Scientific, Pittsburgh, PA, USA) were precoated with the
capture anti-PD-1 mAb (4B9) [31, 34] at 3 μg/ml in
0.05 M carbonate buffer solution (pH 9.6) overnight at
4 °C. The coating solution was aspirated off, and un-
occupied binding sites on the plates were blocked with
2 % bovine serum albumin in PBS at 37 °C for 1 h. After
being washed three times with PBS containing 0.2 %
Tween-20, samples and standards (PD-1 fusion proteins;
R&D Systems) were added to the wells for 2 h at 37 °C
in duplicate. The specific binding protein was detected
with biotinylated anti-PD-1 mAb (bio-9H1, 1 μg/ml)
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[31, 34] for 1 h at 37 °C, followed by streptavidin-
horseradish peroxidase at 1:2000 for 1 h at 37 °C, and then
revealed with the substrate 3,3′,5,5′-tetramethylbenzidine
(Sigma-Aldrich, St. Louis, MO, USA). The reaction was
stopped with 2 M H2SO4, and the plates were analyzed at
450 nm using a microplate reader (Bio-Rad Laboratories,
Hercules, CA, USA). The plates were washed five times
with PBS containing 0.2 % Tween-20 after each step. The
serial twofold dilutions of the soluble CD28-Fc, PD-L1-Fc,
and PD-L2-Fc proteins starting from 100 ng/ml were
detected by the ELISA to assess the specificity of the
established system. For the detection of serum expression
of TNF-α, IFN-γ, and IL-17A, high-sensitivity ELISA kits
for soluble cytokines were obtained from eBioscience and
used according to the manufacturer’s instructions.
Assessment of PD-1 function
The effects of PD-1 crosslinking during T-cell activation
were determined according to the method described by
Bertsias et al. [20]. CD4+ T cells (1 × 105/well) stimulated
in 96-well plates with plate-bound anti-CD3 (1 μg/ml)
and soluble anti-CD28 (250 ng/ml) were incubated with
a pool of L929-PD-L1 cells (PD-L1 transgenic cell line)
or with various concentrations of plate-bound PD-L1-Fc
(0.5 μg/ml; R&D Systems), a chimeric protein containing
the extracellular part of human PD-L1 linked to the Fc
fragment of human immunoglobulin G1 (IgG1). Then
the above CD4+ T cells were incubated in the presence
or absence of the recombinant fusion protein PD-1-Fc
for 4 days. After 3 days of coculture supernatants were
collected for cytokine measurements, and after 4 days
cells were pulsed with the reagent of Cell Counting
Kit-8 (CCK-8; Dojindo Molecular Technologies,
Kumamoto, Japan) for another 4 h to measure
proliferation.
Induction of CIA and treatment of DBA/1 mice with PD-1-Fc
Male DBA/1 mice were purchased from the Chinese
Academy of Sciences (Beijing, China) and maintained in
a specific pathogen-free animal facility at Soochow Uni-
versity. All animal procedures were approved by the In-
stitutional Animal Care and Use Committee of Soochow
University for the use of laboratory animals. CIA was in-
duced according to the standard protocol. Briefly, an
emulsion was formed by dissolving 2 mg/ml chick type
II collagen (CII; Sigma-Aldrich) overnight at 4 °C in
10 mM acetic acid and combining it with an equal vol-
ume of complete Freund’s adjuvant containing 5 mg/ml
heat-killed Mycobacterium tuberculosis (Difco H37Ra;
BD Diagnostics, Sparks, MD, USA). Eight-week-old mice
were injected intradermally at two sites in the base of
the tail with a total of 100 μl of emulsion. This was
repeated as a booster injection 21 days later. In some
experiments, DBA/1 mice received intraperitoneal
injections of a high dose of PD-1-Fc (0.15 mg/mouse, n = 7)
or a low dose of PD-1-Fc (0.05 mg/mouse, n = 7) on days 1,
3, and 5 postimmunization. PD-1-Fc protein consists of the
extracellular domains of murine PD-1 linked to the Fc frag-
ment of mouse IgG1. Animals were assessed for redness
and swelling of all four limbs, and a clinical score ranging
from 0 (no inflammation) to 4 (extensive swelling and ery-
thema of the entire paw) was assigned to each mouse two
or three times per week for up to 42 days. After the mice
were killed, their rear paws were removed, fixed, decalcified,
and embedded in paraffin. Frontal sections of the paw tis-
sue (5 mm) were stained with hematoxylin and eosin and
evaluated according to the presence or absence of inflam-
matory cell infiltrates (defined as focal accumulations of
leukocytes).
CII-specific T-cell proliferation and cytokine production
Five days or ten weeks after the second immunization,
the spleen was removed. Single-cell suspensions of
erythrocyte-depleted splenocytes were prepared in RPMI
1640 medium supplemented with 10 % FBS, 2 mM glu-
tamine, 1 mM sodium pyruvate, and antibiotics. Whole
splenocytes were seeded into 96-well flat-bottom micro-
titer plates and cultured in the presence or absence of
the indicated amounts of denatured (60 °C, 30 minutes)
bovine CII for 72 h. PD-1-Fc protein was added at the
start of the assay. CCK-8 was added (10 μl/well), and in-
cubation was continued for 2 h, followed by measure-
ment of absorbance at 450 nm. Supernatants from
similar cultures were collected after 96 h for assessment
of cytokine production using a cytometric bead array
(CBA; BD Biosciences, San Jose, CA, USA).
Cytometric bead array
Cytokine concentrations in supernatants were deter-
mined using a mouse Th1/Th2/Th17 CBA kit (BD Bio-
sciences), which allowed for the simultaneous detection
of IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IL-17A.
Aliquoted samples were thawed, and CBA analysis was
performed according to the manufacturer’s protocol.
Briefly, beads coated with capture antibodies were
mixed, and 50 μl of the capture bead mixture was added
to 50 μl of sample. To these sample bead complexes,
50 μl of phycoerythrin (PE)-conjugated detection anti-
body was added, and this mixture was incubated for 3 h
in the dark at room temperature. Samples were washed
with 1 ml of wash buffer at 1100 rpm for 5 minutes, and
the pellets were resuspended in 300 ml of wash buffer.
Cytokine standards were serially diluted to facilitate the
construction of calibration curves necessary for deter-
mining protein concentrations of test samples. Flow
cytometric analysis was performed on a BD FACSCanto II
(BD Immunocytometry Systems, Erembodegem, Belgium)
with BD FACSDIVA version 6 software, and data were
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analyzed with FCS Express version 3 software (De Novo
Software, Glendale, CA, USA).
Antibodies and flow cytometry
Human cells were stained with the following antibodies:
fluorescein isothiocyanate (FITC)-anti-CD4, PE-cyanine
7 (Cy7)-conjugated anti-IFN-γ, anti-IL-4, anti-IL-17A,
and anti-TNF-α (all from BioLegend, San Diego, CA,
USA). Mouse cells were stained with FITC-conjugated
anti-CD4, PE-anti-chemokine (C-X-C) motif receptor 5,
PE-Cy7-conjugated anti-inducible costimulatory mol-
ecule, anti-IFN-γ, anti-IL-4, anti-IL-17A, and anti-TNF-α
(all from BioLegend).
Intracellular staining was performed as follows.
PBMCs or splenocytes were stimulated with 50 ng/ml
phorbol 12-myristate 13-acetate, 750 ng/ml ionomycin
(both from Sigma-Aldrich), and 1 μl/ml GolgiStop
(BD Biosciences) for 5 h at 37 °C. Surface staining was
performed for 20 minutes with FITC anti-human/anti-
mouse CD4 antibody on ice. Cells were washed and
resuspended in fixation/permeabilization solution (BD
Cytofix/Cytoperm kit; BD Biosciences) and stained
with PE-Cy7-conjugated anti-IFN-γ, anti-IL-4, anti-IL-
17A, and anti-TNF-α (all from BioLegend) for flow
cytometric analysis. PE-Cy7-conjugated IgG1 and
FITC-conjugated IgG1 (BD Biosciences) were used as
isotype controls. All data were analyzed using FlowJo
software (FlowJo, Ashland, OR, USA).
Computed tomographic scanning
Micro–computed tomography was performed using a cone
beam scanner (μCT 20; SCANCO Medical, Brüttisellen,
Switzerland) with a fixed x-ray fan beam of 7-μm spot size
at 50 kVp and 160 mA. Integration time was 140 millisec-
onds, and slices were scanned at high resolution (1024 ×
1024–pixel matrix per slice) and size of 25 microvoxels.
Histological and radiological assessments of arthritis
CIA mice were killed at day 35 or day 60. Anteroposter-
ior radiographs of the four limbs were obtained with a
cabinet soft x-ray apparatus (CMB-2; Softex, Tokyo,
Japan). The hind paws were then removed, fixed in for-
malin, decalcified in 10 % ethylenediaminetetraacetic
acid, embedded in paraffin, sectioned, and stained with
hematoxylin and eosin.
Statistical analysis
All statistical analyses were performed using IBM SPSS
20.0 for Windows software (IBM, Armonk, NY, USA).
All the quantitative data are presented as mean ± stand-
ard deviation. Student’s t test was used to analyze differ-
ences between the groups. A Mann–Whitney U test
based on nonparametric analysis was performed for
independent samples. A paired-samples t test or
nonparametric Wilcoxon signed-rank test was per-
formed for paired samples. For multiple comparisons,
one-way analysis of variance or the Kruskal–Wallis test
was initially performed to determine whether an overall
statistically significant change existed before using the
paired or unpaired Student’s t test. For correlation ana-
lyses, a Spearman’s r value derived from Pearson’s r was
calculated. A p value less than 0.05 was considered
statistically significant.
Results
sPD-1 levels correlate with clinical parameters and
cytokine concentration in sera and SF of patients with RA
Higher concentrations of sPD-1 were detected in the SF
and serum of patients with RA than in OA-SF (p < 0.0001)
and control serum specimens (p = 0.038) (Fig. 1a).
The levels of sPD-1 in serum specimens from Mo-RA
(p = 0.017) and Hi-RA (p = 0.048) patients were higher
than those in Re-RA patients and Lo-RA patients (Fig. 1b).
Clinical analyses showed that sPD-1 levels were correlated
with DAS28 (r = 0.545, p < 0.001) and RF content
(r = 0.306, p = 0.005) (Fig. 1d, e). MTX treatment
significantly reduced sPD-1 level compared with
pretherapy levels (p = 0.011) (Fig. 1f ). In addition,
sPD-1 levels in RA serum samples correlated significantly
with the concentrations of TNF-α, IFN-γ, and IL-17A in
the same serum samples (Fig. 1g–i). These results suggest
that sPD-1 is aberrantly expressed in RA serum, and the
level of sPD-1 correlates with the serum concentrations of
TNF-α, IFN-γ, and IL-17A. Taken together, these results
suggest that high levels of circulating sPD-1 are observed
in RA and may be associated with disease severity and
activity.
Induction of PD-1Δex3 splicing variants by proinflammatory
cytokines
Next, we examined the expression of PD-1Δex3. The
PD-1Δex3 splice variant lacks the membrane-spanning
domain but has an unchanged extracellular domain, sug-
gesting that the putative translational product is sPD-1
[25]. We found that patients with RA had increased ex-
pression of PD-1Δex3 compared with patients with OA
and healthy controls (p < 0.028) (Fig. 2a). It has been
shown that proinflammatory cytokines might be respon-
sible for the progression of arthritis [6]. We found that
the mRNA levels of the genes encoding the proinflam-
matory cytokines IFN-γ, TNF-α, IL-4, IL-21, and IL-17A
were higher in the PBMCs of patients with RA (Fig. 2b),
and the IFN-γ, TNF-α, IL-10, and IL-17A mRNA levels
were positively correlated with the mRNA level of PD-
1Δex3 (Fig. 2c–h). We hypothesized that these proin-
flammatory cytokines, which are expressed abundantly
in RA serum, might be responsible for the induction of
increased expression of PD-1Δex3 in T cells in RA.
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Thus, we analyzed the ability of the proinflammatory cy-
tokines IFN-γ, TNF-α, and IL-17A to induce expression
of PD-1Δex3 in vitro in PBMCs obtained from healthy
individuals. As shown in (Fig. 2i–k), the expression of
PD-1Δex3 in T cells could be selectively induced by
IFN-γ, TNF-α, and IL-17A in a dose-dependent manner,
whereas the expression of flPD-1 was not significantly
affected by the addition of the indicated cytokines.
sPD-1 block PD-1 pathway in vitro
CD4+ T cells were incubated with a pool of L929-PD-L1
cells or with PD-L1-Fc protein in the presence or absence
of the recombinant fusion protein PD-1-Fc (PD-1-Fc) for
4 days, then cocultured with CCK-8 for the proliferation
assay. PD-1-Fc promoted proliferation of CD4+ T cells
cocultured with PD-L1 transgenic cells (p = 0.0074) (Fig. 3a).
Meanwhile, T-cell suppression by PD-L1-Fc was neutralized
by PD-1-Fc (p < 0.05) (Fig. 3b). PBMCs from patients with
RA and healthy controls were incubated with anti-CD3 in
the presence or absence of PD-1-Fc for 4 days with the
addition of brefeldin A for the last 16 h. The cells were then
collected and stained for the cell surface marker CD4, as
well as for the intracellular cytokines IFN-γ, TNF-α, IL-4,
and IL-17 after fixation/permeabilization. We found that
PD-1-Fc increased the percentage of CD4+IFN-γ+ and
CD4+IL-17+ cells (Fig. 3c), suggesting that sPD-1 has the
ability to promote Th1/Th17 cells, which are critical
pathogenic T cells in autoimmune diseases, including RA.
























































































































































Fig. 1 Detection of soluble programmed cell death 1 (sPD-1) protein in synovial fluid (SF) and serum of patients with rheumatoid arthritis (RA)
and controls. a Concentrations of sPD-1 were analyzed in SF or serum of patients with RA or controls [osteoarthritis (OA) or healthy controls (HC)]
by enzyme-linked immunosorbent assay. Horizontal bars represent the mean concentration within a given group. b The levels of sPD-1 in serum
specimens from patients with moderate rheumatoid arthritis activity (Mo-RA; 3.2 < 28-joint Disease Activity Score≤ 5.1) (p = 0.017) and patients
with high rheumatoid arthritis activity (Hi-RA; 28-joint Disease Activity Score >5.1) (p = 0.048) were higher than those in remission (Re-RA) or those
with low rheumatoid arthritis activity (Lo-RA; 2.6≤ 28-joint Disease Activity Score ≤ 3.2). c The levels of sPD-1 in serum specimens of patients with
RA did not differ significantly between those with late RA (Late-RA; >12 months duration) and patients with extraarticular manifestations (Extra-RA) or
between those early in the disease course (Early-RA; ≤12 months duration) and patients with limited joint manifestations (Limited-RA). d and
e Correlation of sPD-1 levels with disease activity [28-joint Disease Activity Score (DAS28)] (r = 0.545, p < 0.001) and rheumatoid factor (RF) content
(r = 0.306, p = 0.005). f sPD-1 levels were significantly reduced after methotrexate therapy (p = 0.011). g–i Correlation between serum concentrations of
sPD-1 and tumor necrosis factor (TNF)-α (r = 0.309, p = 0.046), interferon (IFN)-γ (r = 0.395, p = 0.010), and interleukin (IL)-17A (r = 0.433, p = 0.006) in
patients with RA. The r value indicates the calculated regression coefficient




Fig. 2 Expression of the programmed cell death 1 protein lacking exon 3 (PD-1Δex3) splicing variant in T cells and correlation between PD-1Δex3
messenger RNA (mRNA) levels and cytokines. a Expression of PD-1Δex3 was analyzed in peripheral blood mononuclear cells (PBMCs) of patients with
rheumatoid arthritis (RA) (n = 34) or controls [patients with osteoarthritis (OA), n = 18; healthy controls (HC), n = 21) by real-time polymerase
chain reaction (RT-PCR). Horizontal bars represent the mean mRNA level within a given group. b Expression of cytokines was analyzed in PBMCs of patients
with RA or controls (OA or HC) by RT-PCR. Asterisks indicate statistically significant differences between the groups (p< 0.05). c–h Correlation of PD-1Δex3
mRNA levels with cytokine mRNA levels. The r value indicates the calculated regression coefficient. i–k Mononuclear cells from healthy volunteers were
incubated with 0–100 ng/ml of the indicated recombinant human cytokines for 12 h and 24 h. CD4+ T cells were then purified for RT-PCR analysis. flPD-1
full-length isoform of programmed cell death 1 protein, TNF-α tumor necrosis factor α, IFN-γ interferon γ, IL interleukin
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Systemic administration of sPD-1 to CII-immunized mice
accelerates arthritis onset and joint damage, and increases
autoantibody production and Th1/Th17 responses
To directly assess the role of sPD-1 in inflammatory
arthritis in vivo, CIA was induced in DBA/1 mice,
followed by intraperitoneal injection with either sol-
uble murine PD-1-Fc fusion protein or PBS as a con-
trol. PD-1-Fc-treated mice developed more severe
arthritis. Administration of only three doses of PD-1-
Fc, starting at day 1 after the second immunization,
markedly exacerbated arthritis progression associated
with severe synovial hyperplasia, cartilage damage, and
bone erosion (Fig. 4a, g). On computed tomographic
scans, we detected obvious narrowing of the joint
space and bone erosion compared with IgG-treated
controls (Fig. 4e, f ). To evaluate whether PD-1-Fc
could affect established arthritis, we treated mice with
established inflamed limbs at a clinical score of 8.0 ±
2.0 with PD-1-Fc. PD-1-Fc rapidly enhanced arthritic
progression with significantly increased joint damage
(Fig. 4b, c).
Immunization with CII elicits a specific humoral re-
sponse in all mice. Although levels of anti-CII antibody
are not strictly correlated to arthritis scores, they are usu-
ally high in sera from severely diseased mice. Serum levels
of anti-CII autoantibody in DBA/1 and CIA mice treated
with PBS or PD-1-Fc were analyzed using ELISA at day 50
after the second immunization. The PD-1-Fc-treated mice
had significantly increased serum levels of anti-CII auto-
antibody compared with the controls (p < 0.05) (Fig. 5a).
Analysis of spleen cells from PD-1-Fc–treated mice re-
vealed significantly upregulated mRNA levels of TNF-α,
IFN-γ, and IL-17 F. Expression of RAR-related orphan re-
ceptor α and T-bet mRNA was also markedly increased
(Fig. 5b). In the PD-1-Fc–treated group, we found signifi-
cantly increased numbers of Th1 and Th17 cells in the
spleen (Fig. 5c, d).
To better understand how PD-1-Fc influences the T-cell
response, we studied the effect of PD-1-Fc on the prolifera-
tion and cytokine secretion of splenocytes in vitro. We cul-
tured splenocytes from CIA mice with or without PD-1-Fc
and found that PD-1-Fc treatment enhanced the ability of
Fig. 3 In vitro blocking using PD-1-Fc increases the proliferative and cytokine-producing capacity of CD4+ T cells from patients with rheumatoid
arthritis (RA). a and b CD4+ T cells were incubated with ligands L929-PD-L1 cells or PD-L1-Fc in the presence or absence of PD-1-Fc for 4 days.
The in vitro proliferative response of CD4+ T cells from patients with RA to L929-PD-L1 cells or to PD-L1-Fc (0.5 μg/ml) was analyzed in the absence or
presence of PD-1-Fc (0–1 μg/ml) using the Cell Counting Kit-8 method. OD optical density. The p value was calculated using the Mann–Whitney U test.
Values are the mean ± standard deviation. *p < 0.05 versus controls. c Aliquots of peripheral blood mononuclear cells from patients with RA (n = 5) and
healthy controls (HC) (n = 5) were incubated with a pool of CD3 antibody in the presence or absence of PD-1-Fc for 4 days. Brefeldin A was added for
the last 16 h. The cells were then collected and stained for the cell surface markers CD4 and PD-1 and for the intracellular cytokines interferon (IFN)-γ,
tumor necrosis factor (TNF)-α, interleukin (IL)-4, and IL-17A after fixation and permeabilization. PD-1 programmed cell death 1
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splenocytes to proliferate (Fig. 6a). After 4 days of culture
IL-2, IL-4, IL-6, TNF-α, IL-17A, and IFN-γ, levels were
quantified in the supernatants. As shown in Fig. 6b, one of
the main effects of PD-1-Fc was to increase the production
of IL-2, IL-6, TNF-α, IL-17A, and IFN-γ proteins. IL-4 pro-
duction was not modified in the presence of PD-1-Fc
(Fig. 6b, c). These results were further confirmed by intra-
cellular cytokine staining (Fig. 6d). These results suggest
that PD-1-Fc promotes CIA by enhancing Th1 and Th17
responses.
Discussion
PD-1 and its ligands PD-L1 and PD-L2 are critical for
tolerance and immune homeostasis by inhibiting T-cell
activation [10, 12]. PD-1−/− mice develop many kinds of
autoimmune diseases [14–16].
Recent reports showed that sPD-1 can block the PD-
1/PD-L1 pathway in regulating T-cell function during
chronic infection, antitumor immunity, and autoimmune
diseases [26–29]. He et al. found that sPD-1 can bind
PD-1 ligands, block PD-1/ligand interactions, and
enhance the cytotoxicity of tumor-specific CTLs [28].
sPD-1 rescues the proliferative response of simian im-
munodeficiency virus–specific CD4+ and CD8+ T cells
during chronic infection [29]. Previously, we demon-
strated the overexpression of PD-1 on CD4+ and CD8+
T cells and elevated serum levels of sPD-1 in patients
with aplastic anemia [31]. We propose that upregulation
Fig. 4 Systemic administration of PD-1-Fc to type II collagen (CII)-immunized mice accelerates arthritis onset and joint damage. a Mean clinical
scores of arthritis for all four limbs in collagen-induced arthritis (CIA) mice that received 50 μg (n = 7) or 150 μg (n = 7) of PD-1-Fc in phosphate-
buffered saline (PBS) intravenously for 5 consecutive days beginning on day 1 after the second immunization with CII. Adjuvant-immunized controls
were treated with immunoglobulin G (IgG) (n = 7). b Mean clinical scores of arthritis for all four limbs in CIA mice that received 50 μg (n = 5) or 150 μg
(n = 5) of PD-1-Fc in PBS intravenously for 5 consecutive days beginning on day 1 after the first treatment. Controls were treated with IgG
(n = 5). c Mean clinical scores of arthritis for all four limbs in CIA mice that received 25 μg of PD-1-Fc in PBS locally injected into the limbs
(n = 3) for 3 consecutive days beginning on day 1 after the first treatment. Controls were treated with IgG (n = 3). d Photographs of CIA mice
on day 39 after the second CII immunization. These animals were treated with PD-1-Fc (lower and middle photographs) or IgG (top photograph).
e and f Representative computed tomographic scans of hind paws from the experiment shown in (a) at day 39 after the second immunization.
g Representative hematoxylin and eosin–stained joint sections from the experiment shown in (a) on day 50 after the second immunization. PD-1
programmed cell death 1 protein
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of sPD-1 molecules might block the PD-1/PD-L1 signal-
ing pathway. Few data are available concerning serum
sPD-1 in RA. Recent studies demonstrated that synovial
and serum sPD-1 levels are elevated in patients with RA
and are correlated with titers of RF [32, 33]. However,
the expression and clinical significance of sPD-1 in RA
are not well known.
We therefore first explored the clinical significance of
sPD-1 in patients with RA by determining the levels of
sPD-1 in serum samples. Both sPD-1 levels in serum
samples and PD-1Δex3 mRNA expression in PBMCs
from patients with RA were elevated compared with
those from patients with OA and healthy controls. Clin-
ical analyses showed that sPD-1 levels were closely cor-
related with disease activity and RF content in patients
with RA. The significant correlation between sPD-1 and
the DAS28 suggests that sPD-1 may be a marker of dis-
ease activity. This result confirms a previous study show-
ing that circulating sPD-1 is derived, at least in part,
from inflamed synovium [31] and that serum sPD-1 may
reflect RA disease activity because it is associated with
synovial inflammation observed on clinical examination
[32]. Our findings suggest that aberrant overexpression
of sPD-1 might block the PD-1/PD-L1 inhibitory
Fig. 5 Systemic administration of PD-1-Fc to type II collagen (CII)-immunized mice accelerates arthritis onset, increases autoantibody production,
and elevates Th1/Th17 responses. a Serum levels of anti-CII autoantibodies were determined by performing enzyme-linked immunosorbent assays
in DBA/1 and collagen-induced arthritis (CIA) mice treated with phosphate-buffered saline or PD-1-Fc on day 50 after the second immunization.
Values are the mean ± standard deviation (SD). *p < 0.05, **p < 0.01 versus controls. b Expression of T-bet, GATA3, RAR-related orphan receptor α
(ROR-a), Bcl-6, interferon regulatory transcription factor (IRF)-6, interleukin (IL)-17 F, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and IL-4 was
determined using real-time polymerase chain reactions in splenocytes obtained from each mouse and normalized to β-actin expression. Values
are the mean ± SD (n = 3 samples per group) and are representative of at least three independent experiments with similar results. c and d Cells
were isolated from the spleen on day 20 of the experiment shown in Fig. 4a and stimulated immediately with phorbol 12-myristate 13-acetate
and ionomycin in the presence of GolgiStop before intracellular staining for IL-17A, IFN-γ, and IL-4. Cells were gated on the CD4+ T-cell population and
analyzed by flow cytometry. Representative dot plots from four sets of similar results are shown. Bars show the mean and SD. *p < 0.05. PD-1
programmed cell death 1 protein, CXCR5 chemokine (C-X-C) motif receptor 5, ICOS inducible costimulatory molecule
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Fig. 6 PD-1-Fc promotes the expansion of Th1 and Th17 cells in vitro. a The proliferation rates of spleen lymphocytes from collagen-induced
arthritis (CIA) mice cultured with type II collagen (CII) or CD3 and PD-1-Fc were determined by Cell Counting Kit-8 assay. Bars show the mean and
standard error of the mean. *p < 0.05 versus control. b and c Cytokine levels in supernatants of spleen lymphocytes from CIA mice that were
stimulated with CII or CD3 antibody in the presence of PD-1-Fc, as determined by cytometric bead array. Data are representative of three
individual sample analyses. Bars show the mean and standard deviation (SD). *p< 0.05. d Percentage of Th1, Th2, and Th17 cells in CD4+ T cells from
spleen lymphocytes of CIA mice with or without PD-1-Fc induction. Percentages were determined by intracellular staining. Data are representative of three
individual sample analyses. Bars show the mean and SD. *p< 0.05 versus control. IFN interferon, IgG immunoglobulin G, IL interleukin, OD optical density,
PD-1 programmed cell death 1 protein, TNF tumor necrosis factor
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pathway and may be associated with persistent activation
of self-reactive T cells in RA, leading to long-term dis-
ease progression. We also showed that the PD-1Δex3
splice variant encoding for sPD-1 is specifically associ-
ated with RA but is not related to the T-cell activation
state, because expression of this variant is markedly
increased in T cells derived from RA [31].
A significant portion of this study was devoted to
investigating the molecular mechanism of higher expres-
sion of sPD-1 in activated CD4+ T cells. It was previ-
ously shown that proinflammatory cytokines might be
responsible for the progression of arthritis. We found
that the proinflammatory cytokines produced abun-
dantly in RA serum might be responsible for inducing
the increased expression of PD-1Δex3 in CD4+ T cells.
Upregulated expression of PD-1 in RA does not appear
to suppress the function of T cells. We therefore hypoth-
esized that the expected function of PD-1 overexpression
in T cells was neutralized. To test this hypothesis, we ex-
amined the effect of a recombinant fusion protein con-
taining the extracellular domain of PD-1 (as encoded by
the PD-1Δex3 variant) on T-cell proliferation and in the
CIA mouse model. Addition of PD-1 fusion protein
enhanced T-cell proliferation in vitro (p < 0.05). This
finding indicated that the regulatory properties of
membrane-bound PD-1 and PD-L1 were altered by the
presence of their soluble forms in the experimental
system.
PD-1 blockade was found to shift antigen-induced cel-
lular reactivity toward a proinflammatory Th1/Th17 re-
sponse, as evidenced by enhanced production of IFN-γ,
IL-2, TNF-α, IL-6, and IL-17A, and to reduce produc-
tion of the Th2 cytokines IL-5 and IL-13 [35]. We
showed that PD-1-Fc enhanced the severity of auto-
immune arthritis in mice with CIA. Additionally, levels
of pathogenic IgG autoantibody to mouse type II colla-
gen were increased in PD-1-Fc-treated CIA mice, and
levels of Th1 and Th17 cells were increased in the
spleen, suggesting that the T cells may have systemic ef-
fects on the B-cell response as well as local effects on
the inflammatory environment. This work demonstrates
that CD4+ T cells specific for sPD-1 can amplify disease
severity after onset of CIA.
Conclusions
We provide evidence that sPD-1 plays a key inhibitory
role in the PD-1/PD-L1 pathway in regulating T-cell
function in RA. sPD-1 occurred at high concentrations
in the serum and SF of patients with RA. It blocked the
regulatory effect of membrane-bound PD-1 on T-cell ac-
tivation. We identified IFN-γ, TNF-α, and IL-17A as in-
ducers of sPD-1. sPD-1 aggravated progression of CIA
through induction of Th1/Th17 responses. sPD-1 regu-
lated peripheral T-cell responses in both human and
murine RA. Thus, sPD-1 may represent an additional
target for immunomodulatory therapy in RA.
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